Drugs

FDA, African Medicines Agency Agreement on Regulatory Harmonization

FDA and the African Medicines Agency (AMA) have signed a Statement of Cooperation establishing a formal framework for collaboration between the U.S. regulator and Africa's continental medicines agency. The agreement is intended to strengthen regulatory convergence, information sharing, and harmonization efforts as the AMA continues to build its role overseeing medical product regulation across the continent, according to FDA.

Under the agreement, the agencies will collaborate on a range of regulatory initiatives, including reliance-based regulatory pathways, oversight of clinical trials for innovative medical products, emergency regulatory response activities, quality management systems, digital transformation, and efforts to combat substandard and falsified medicines.

FDA says the cooperation framework reflects a shared commitment to science-based regulatory approaches and recognizes the growing importance of regulatory reliance, a model that allows health authorities to leverage assessments, inspections, and regulatory decisions made by trusted counterparts while maintaining independent decision-making authority.

As AMA develops continent-wide regulatory frameworks, the agency may have opportunities to rely on FDA scientific and regulatory decisions to support more efficient review processes and reduce duplication of effort, according to the announcement.

The cooperation comes as Africa's pharmaceutical market is projected to exceed $50 billion by 2030, increasing demand for regulatory systems capable of ensuring the safety, quality, and effectiveness of medicines while facilitating access to innovative products.

FDA said more transparent and harmonized regulatory pathways could help reduce barriers to market entry, expand access to quality-assured medical products, and create additional opportunities for U.S. pharmaceutical and medical product companies operating in African markets.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome